-$0.25 Earnings Per Share Expected for Kadmon Co. (KDMN) This Quarter

Equities analysts expect Kadmon Co. (NYSE:KDMN) to report earnings of ($0.25) per share for the current quarter, according to Zacks. Two analysts have made estimates for Kadmon’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.23). Kadmon reported earnings of ($0.39) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 35.9%. The firm is scheduled to announce its next quarterly earnings results on Monday, May 21st.

On average, analysts expect that Kadmon will report full year earnings of ($1.11) per share for the current year, with EPS estimates ranging from ($1.25) to ($0.96). For the next year, analysts expect that the business will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.29) to ($0.38). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Kadmon.

How to Become a New Pot Stock Millionaire

Kadmon (NYSE:KDMN) last announced its earnings results on Tuesday, March 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.12. The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $3.07 million. During the same period in the prior year, the business earned ($0.50) earnings per share. The company’s revenue for the quarter was down 65.1% compared to the same quarter last year.

Several brokerages have recently issued reports on KDMN. Zacks Investment Research raised Kadmon from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 10th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon in a research report on Friday, December 15th. Piper Jaffray reaffirmed a “positive” rating and set a $9.00 target price (up from $7.00) on shares of Kadmon in a research report on Tuesday, February 13th. Finally, Jefferies Group raised their target price on Kadmon to $16.00 and gave the company a “buy” rating in a research report on Tuesday, February 13th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Kadmon presently has an average rating of “Hold” and an average target price of $11.45.

Shares of Kadmon stock opened at $3.92 on Friday. Kadmon has a 1 year low of $2.05 and a 1 year high of $5.86. The firm has a market cap of $316.93, a PE ratio of -2.76 and a beta of 3.97.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new stake in Kadmon in the 3rd quarter worth about $119,000. BlueCrest Capital Management Ltd purchased a new position in Kadmon during the 4th quarter valued at about $241,000. Wells Fargo & Company MN grew its holdings in Kadmon by 23.2% during the 3rd quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock valued at $247,000 after buying an additional 13,923 shares in the last quarter. BlackRock Inc. grew its holdings in Kadmon by 151.2% during the 4th quarter. BlackRock Inc. now owns 208,190 shares of the company’s stock valued at $754,000 after buying an additional 125,308 shares in the last quarter. Finally, Sawtooth Solutions LLC purchased a new position in Kadmon during the 4th quarter valued at about $799,000. 61.71% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “-$0.25 Earnings Per Share Expected for Kadmon Co. (KDMN) This Quarter” was published by Week Herald and is owned by of Week Herald. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://weekherald.com/2018/04/14/0-25-earnings-per-share-expected-for-kadmon-co-kdmn-this-quarter.html.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply